Effect of pentoxifylline on endothelaemia and hypothalamic-pituitary-adrenocortical axis activation in female rats under stress exposure.
Endothelial dysfunction may belong to negative consequences of stress exposure accompanied by activation of several stress systems including the hypothalamic-pituitary-adrenocortical (HPA) axis. The present experiments were aimed at testing the hypotheses that i) immobilization (IMO) stress results in sustained increase in endothelaemia for 24 h and that ii) pentoxifylline, a drug with endothelium protective properties, attenuates the rise in endothelaemia and HPA axis activation in female rats as shown previously in males. Circulating endothelial cells increased immediately after the IMO for 2 h, returned back to control levels at 12 h and increased again at 24 h. Stress-induced rise in adrenocorticotropic hormone (ACTH) and corticosterone levels was particularly high immediately after the IMO. Pretreatment with pentoxifylline (20 mg/kg subcutaneously for 7 days) attenuated the rise in endothelaemia and adrenal corticosterone measured at 24 h following IMO. Plasma levels of ACTH and proopiomelanocortin gene expression in the anterior pituitary were not affected by pentoxifylline treatment. The present results indicate that IMO stress in female rats induces a biphasic rise in endothelaemia early at the time of stress exposure and than 24 h thereafter. Based on these data and our previous study we can conclude that intensive stress has a negative influence on endothelial cells in both sexes and no gender differences seem to be present in the protective action of pentoxifylline.
Kristova
V
V
Department of Pharmacology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. viera.kristova@fmed.uniba.sk
Kiss
A
A
Pirnik
Z
Z
Kriska
M
M
Jezova
D
D
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000818:Animals; D002452:Cell Count; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000097:blood / Q000235:genetics; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000473:pathology; D005260:Female; D015870:Gene Expression / Q000235:genetics; D006401:Hematologic Agents / Q000494:pharmacology*; D019417:Hindlimb Suspension; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology*; D007103:Immobilization; D017403:In Situ Hybridization; D010431:Pentoxifylline / Q000494:pharmacology*; D010913:Pituitary-Adrenal System / Q000502:physiology*; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley; D013315:Stress, Psychological / Q000503:physiopathology*; D013997:Time Factors
D006401:Hematologic Agents; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D010431:Pentoxifylline; D003345:Corticosterone